The potentials of Etlingera elatior rhizome as an antidiabetic agent have been performed in the current study using anti α-glucosidase, anti α-amylase, anti-oxidation, and anti-inflammation activities. The macerated ethanolic crude extract (EE) and five fractions with different polarities, partitioned with n-C6H6 (F1), CH2Cl2 (F2), EtOAc (F3), n- BuOH (F4), and H2O (F5), were prepared to be tested the biological activities. The results indicated that all crude extracts exhibited good inhibition for both α-glucosidase and α-amylase in the range of 28.36-99.79% and 35.91- 58.13% at the concentration as 25 μg/mL, respectively. Most of them displayed equipotent to 9 fold higher than standard acabose, especially for anti α-glucosidase activity. Due to widely distribution of flavonoids in all partitioned extracts, flavonoids might play the important roles inα-glucosidase and α-amylase inhibition. EE andnon-polarfractions (F1 and F2), showed the potency in anti-inflammatory activity equal to standard indomethacin with IC50 19.35, 17.79, 21.12and 19.81μg/mL, respectively. It is likely that the presence of terpenoid aglycones in F1 and F2fractions could possess anti-inflammatory activity of E. elatior rhizome. For antioxidation activities, the presence of tannin, phenolic and flavonoid was associated with good activity of EtOAc fraction (F3), when compared with standard ascorbic acid (IC50 12.60 and4.22μg/mL, respectively) whereas F2, F3 and F4 revealed good anti-oxidation profile by FRAP assay. Our findings supported the ability of E. elatior rhizome in development as nutraceutical purpose for utilizing in diabetic care in near future.